Michael P. Johnson's Insider Trades & SAST Disclosures
Michael P. Johnson's most recent trade in Idexx Laboratories, Inc. was a trade of 3,657 Non-Qualified Stock Option (right-to-buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael P. Johnson.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 3,657 | 3,657 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 870 | 870 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 217 | 217 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 179 | 535 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 179 | 585 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 176 | 406 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 176 | 352 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 13 Feb 2025 | 118 | 467 (0%) | 0% | 444.5 | 52,455 | Common Stock |
| Idexx Laboratories, Inc. | Perkins Johnson Michael | EVP and CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 3,132 | 3,132 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Perkins Johnson Michael | EVP and CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 714 | 714 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Perkins Johnson Michael | EVP and CHRO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Perkins Michael Johnson | EVP and CHRO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 176 | 243 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Johnson Perkins Michael | EVP and CHRO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 176 | 528 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Johnson Michael Perkins | EVP and CHRO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.57 per share. | 14 Feb 2024 | 60 | 183 (0%) | 0% | 560.6 | 33,634 | Common Stock |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 4,346 | 4,346 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 804 | 804 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 704 | 4,086 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Michael Perkins Johnson | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 3,382 | 3,382 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges